linjc16/ctgov huggingface dataset:
Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs

Study Overview
=================
Brief Summary
-----------------
Development of a non-invasive method for the determination of the position of optimal muscle length in the different muscles of the shoulder. Analysis of the adaptation of the muscle to a new optimal length in patients with a shoulder prosthesis.

Official Title
-----------------
Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs

Conditions
-----------------
Shoulder Prosthesis

Intervention / Treatment
-----------------
* Procedure: Simultaneous controlled power measurement
* Procedure: Surface EMG measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Shoulder prosthesis Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Simultaneous controlled power measurement|nan|
|Procedure: Surface EMG measurement|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of the optimal length of the muscles of the shoulder |  |  |
Longitudinal Study of Weight Change Following Lower Limb Amputation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess weight change in a population of Veterans with amputations. Little is known about the how weight changes following an amputation. It is widely believed that many patients experience weight gain following amputation. This study aims to identify magnitude of weight changes following amputation and determine characteristics associated with weight gain. Information on weight change trajectories would be useful to better understand long-term health consequences associated with amputation and to design and target interventions to encourage weight maintenance and general health promotion for groups at high risk of weight gain.

Official Title
-----------------
Weight Change, Physical Activity and Health Promotion in Veteran Amputees

Conditions
-----------------
Amputation Wound, Traumatic Amputation of Toe, Dysvascular Amputation of Lower Limb

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Exposed cohort: incident lower limb amputation during the study period (1/1997-12/2008) in VISN 20 >= 1 plausible weight recoded in the medical record at baseline (defined as 8 weeks before amputation or 2-8 weeks post amputation) >=1 weight measured post amputation (2 months to 42 months post amputation) Unexposed (comparison) cohort: no lower limb amputation during the study period no prior history of amputation >= 2 plausible recorded weights including at least one in the 2-6 weeks after their reference date (baseline). Alive at least 18 months after baseline Exclusion Criteria: female (due to small number of women with lower limb amputations) lack information on any of the characteristics used for matching (e.g., birth year/age and height to calculate body mass index)

Ages Eligible for Study
-----------------
Minimum Age: 27 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Underwent a procedure at a VA medical facility in VISN 20 for a lower limb amputation between 1997 and 2008 | |
| Group 2<br>No history of lower limb amputation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| % Weight Change From Baseline | Time window for 3 years is 31-39 months after baseline | At  3 years after baseline |
Research Tissue Bank

Study Overview
=================
Brief Summary
-----------------
This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: Peripheral blood Bone marrow Bone marrow biopsy A phlebotomized unit of blood Spleen cells Toenail clippings This material will be used for the study of Myeloproliferative Disorders (MPD) by researchers. The goals of this research study are to understand the causes of MPDs, how to diagnose them more easily and how to treat them better. MPD is a disease affecting hematopoietic stem cells. Hematopoietic stem cells are cells that make blood cells. These stem cells grow in the center portion of the bones called bone marrow. Under some conditions, these cells are also found in blood. There are several diseases, which are classified as MPD. These include polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in the bone marrow). These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments.

Official Title
-----------------
Research Tissue Bank

Conditions
-----------------
Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) are eligible. Newly diagnose MPD patients as well as previously treated for a MPD are eligible. Signed informed consent is required from each patient at the time of enrollment. Exclusion Criteria: Patients currently participating in experimental treatment arms of MPD-RC protocols, or other experimental treatment protocols are not eligible during the period they are on study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To collect and store tissue specimens from patients with MPDs including PV, IM, ET. The samples will be used to conduct laboratory investigations to help define mechanisms involved in the pathophysiology and treatment of these disorders. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC). The safety of this treatment will also be studied.

Official Title
-----------------
A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: BMS-275183


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced or metastatic pretreated NSCLC Measurable disease Adequate hematologic, hepatic and renal functions ECOG Performance Status of 0-2 Exclusion Criteria: Inability to swallow capsules Recent significant cardiovascular disease Woman who are pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: BMS-275183|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effects of Therapist Behavior on the Treatment of Depressed Adolescents

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify and evaluate therapist behaviors that affect how well and how long adolescent patients stay in treatment for depression.

Detailed Description
-----------------
Early patient drop out, sporadic attendance, and minimal participation have hindered the development and administration of effective treatments for adolescent depression. Adolescents who do not receive adequate exposure to active treatment are unlikely to benefit from experimentally supported treatments. Certain therapist behaviors may influence the attendance, drop-out, and overall participation of adolescents with depression. This study will evaluate the effect of engagement interventions and alliance on attendance, participation, completion, and outcome in depressed adolescents. Participants in this study will have 12 weekly sessions of cognitive behavioral therapy (CBT) at a school-based health clinic. Audio recordings from the completed CBT sessions will be replayed and evaluated to identify therapist engagement interventions, therapy alliance, and treatment participation.

Official Title
-----------------
Engagement and Alliance in CBT for Depressed Adolescents

Conditions
-----------------
Depression, Depressive Disorder, Dysthymic Disorder

Intervention / Treatment
-----------------
* Behavioral: Cognitive Behavioral Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major depression or dysthymic disorder Referred by school Exclusion Criteria: Comorbid psychosis, bipolar disorder, or mental retardation

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Cognitive Behavioral Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adolescent
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients receive 1 dose of von Willebrand factor concentrate. Timed blood studies are performed for the next 96 hours. Patients are followed every 2 weeks for 16 weeks, and at 24, 36, and 52 weeks.

Conditions
-----------------
Von Willebrand's Disease

Intervention / Treatment
-----------------
* Drug: von Willebrand factor


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: von Willebrand's disease

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: von Willebrand factor|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hematologic disorders, rare disease, von Willebrand's disease
Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare

Study Overview
=================
Brief Summary
-----------------
This is an exempt, retrospective study of a limited set of information obtained from patients' medical records at 10 to 12 substance abuse treatment programs combined with alcohol breath analyzer results during up to 3 years of aftercare monitoring. The study objectives are 1) to compare the compliance rates and likelihood of achieving sustained sobriety for aftercare patients in mandated (eg, impaired professionals) versus non-mandated monitoring programs and 2) identify components within patients' monitoring agreements that are significantly correlated with positive outcomes.

Official Title
-----------------
Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare

Conditions
-----------------
Alcohol Use Disorder

Intervention / Treatment
-----------------
* Other: Soberlink combined with aftercare services


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with a diagnosis of alcohol abuse enrolled into an aftercare program following residential treatment Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mandated impaired professionals<br>Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment. | Other: Soberlink combined with aftercare services<br>* Soberlink Alcohol Breath Analyzer System combined with aftercare services<br>|
| Non-mandated adults<br>A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment. | Other: Soberlink combined with aftercare services<br>* Soberlink Alcohol Breath Analyzer System combined with aftercare services<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance rates (negative versus positive versus false positive alcohol test findings) |  | Test administered 2 to 4 times per day for up to 3 years | 
| Response rates: defined as use of device when prompted-will include several values such as missed, late, excused |  | Test administered 2 to 4 times per day for up to 3 years |
Computed Tomography (CT) in Head and Neck Patients

Study Overview
=================
Brief Summary
-----------------
This study is conducting a comparison of chest x-ray (CXR) and minimum dose thoracic CT (MnDCT) in the detection of lung nodules (metastases) in patients with head and neck carcinoma.

Detailed Description
-----------------
A comparison of chest x-ray (CXR) and minimum dose thoracic CT (MnDCT)in the detection of lung nodules (metastases) in patients with head and neck carcinoma

Official Title
-----------------
Minimum Dose CT in the Detection of Lung Nodules in Patients With Head and Neck Cancer

Conditions
-----------------
Lung Tumors

Intervention / Treatment
-----------------
* Procedure: CT thorax


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with squamous cell carcinoma of the head and neck Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: CT thorax|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of lung metastases |  |  |
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

Study Overview
=================
Brief Summary
-----------------
Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.

Conditions
-----------------
Non-Hodgkin's Lymphoma

Intervention / Treatment
-----------------
* Drug: epratuzumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at least 12 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: epratuzumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Wellnara Post-marketing Surveillance in Japan

Study Overview
=================
Brief Summary
-----------------
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Wellnara for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Wellnara in clinical practice. A total 400 patients will be recruited and followed 3 years since starting Wellnara administration.

Official Title
-----------------
Drug Use Investigation of Wellnara Tablet

Conditions
-----------------
Osteoporosis, Postmenopausal

Intervention / Treatment
-----------------
* Drug: E2/LNG oral (Wellnara, BAY86-5029)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who received Wellnara for postmenopausal osteoporosis Exclusion Criteria: Patients who are contraindicated based on the product label
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Drug (incl. Placebo) | Drug: E2/LNG oral (Wellnara, BAY86-5029)<br>* Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reactions and serious adverse events in subject who received Wellnara |  | After Wellnara administration, up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease) and dose of Wellnara |  | At baseline and after Wellnara administration, up to 3 years | 
| Effectiveness evaluation assessment by the three rank scales: improvement, not changed, and worse |  | At baseline and after Wellnara treatment, up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Wellnara, Postmenopausal osteoporosis
Incisional Hernia Outcomes Study Using Parietex Composite Mesh

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe the outcomes of laparoscopic incisional hernia repair surgery and to record the outcomes of patients after surgery.

Detailed Description
-----------------
For subjects who agree to participate in this study, participation will last for 1 year. Subjects will undergo all the routine preoperative testing, the same as would be required if they were not participating in this study. This testing includes a blood sample and an electrocardiogram (ECG). Follow up visits will be done at 2 weeks after surgery, 6 weeks after surgery, and 1 year after surgery. Except for the 1 year visit, these office visits are routine and would be requested even if you were not participating in this study. At each of these visits, subjects will be asked about their level of pain and the amount and type of pain medication their are taking. Data gathered for this study will be on outcomes only.

Official Title
-----------------
A Multi-Center, Laparoscopic Abdominal-Wall Hernia Repair Outcomes Study Using Parietex Composite Mesh

Conditions
-----------------
Incisional Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: incisional hernia suitable for repair by laparoscopic techniques Exclusion Criteria: not a candidate for laparoscopic surgery hernia not suitable for laparoscopic repair techniques

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Laparoscopic incisional hernia repair<br>Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analog (VAS) scale | pain assessment | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopic surgery